Ongoing Studies
 

I) BCIRG 005
A Multicenter phase III randomized trial comparing Docetaxel in combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin and Cyclophosphamide followed by Docetaxel (AC-T) as adjuvant treatment of operable breast cancer HER2nue negative patients with positive axillary lymph nodes.

II) BCIRG 006
A Multicenter phase III trial comparing Doxorubicin and Cyclophosphamide followed by Docetaxel (AC-T) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (AC-TH) and with Docetaxel, Platinum salt and Trastuzumab (TCH) in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the HER2neu alteration.

III) ZO-FAST
A Multicenter phase III trial comparing addition of Zoledronic acid (whether upfront or delayed) to Letrezole in prevention of osteoporosis in adjuvant treatment of hormonal positive postmenopausal breast cancer

IV) FEMALE STUDY
A Multicenter phase III trial comparing the role of Letrezole as a first line treatment in postmenopausal metastatic breast cancer either alone or concomitant with chemotherapy or sequential following chemotherapy

V) ELECTRA
A Multicenter phase III trial comparing Letrezole alone versus Letrezole and Trastuzumab as a first line treatment in the metastatic setting in postmenopausal hormonal positive breast cancer containing the HER2neu alteration

VI) ABREAST
A Multicenter phase IV trial on breast cancer registration on adjuvant strategies. An observational study to view the clinical pattern of patients with early stage breast cancer and characterize existing and evolving practice patterns

VII) NSCLC retrospective analysis
A retrospective analysis of 150 cases of non small cell lung cancer treated in our facility in the period from 2000-2003. To study the impact of different chemotherapy combination on survival and time to progression

VIII) Rituximab in the management of aggressive non-hodgkin lymphoma
A phase II trial assessing Rituximab based chemotherapy combination in different clinical settings in aggressive non-hodgkin lymphoma carrying poor prognosis.

Copyright © 2004 [Cairo Oncology Center].
Revised: 09/14/05.